Claims for Patent: 10,307,551

Summary for Patent: 10,307,551

Title:	Controlled inhaler for distributing inhalant according to inhalation velocity
Abstract:	An inhaler is provided that includes a controller, a driver, an atomizer and one or more sensors for detecting information about a velocity of inhalation of a user of the inhaler. The controller is configured to dispense an inhalant from the inhaler during an inhalation of the user based on information about the velocity of inhalation of the user. Such information can include a duration of maximum inhalation velocity or an increase or maximum in the acceleration in inhalation velocity. Embodiments of the inhaler can be used to enhance the delivery of drugs and therapeutic agents for those patients having a weakened respiratory system who are unable to take a deep or full breadth, e.g., patients having asthma or COPD. Embodiments of the inhaler can be used to deliver a variety of drugs and therapeutic agents including agents for the treatment of asthma, diabetes, epilepsy and heart disease.
Inventor(s):	Imran; Mir (Los Altos Hills, CA)
Assignee:	InCube Labs, LLC (San Jose, CA)
Application Number:	15/263,768
Patent Claims:	1. A method for operating an inhaler to deliver a therapeutic agent to a user, the method comprising: deriving an inhalation velocity profile for an initial first inhalation, of the user; and dispensing the aerosoled form of the therapeutic agent into the lung of the user during the initial first inhalation, wherein dispensing the aerosoled form of the therapeutic agent during the initial first inhalation is based at least in part on the derived inhalation velocity profile; and signaling the user when a desired amount of the therapeutic agent has been dispensed. 2. The method of claim 1, wherein deriving the inhalation velocity profile includes determining, from the initial first inhalation, at least one of (i) a duration of maximum inhalation velocity of the derived inhalation velocity profile or (ii) a maximum acceleration of the derived inhalation velocity profile. 3. The method of claim 2, wherein dispensing the aerosoled form of the therapeutic agent is during the initial first inhalation is timed to occur at a time of (i) maximum inhalation velocity, or a (ii) maximum inhalation acceleration. 4. The method of claim 1, wherein dispensing the aerosoled form of the therapeutic agent during an initial first inhalation includes delivering a therapeutically effective amount of the therapeutic agent to a deep lung volume of the user. 5. The method of claim 1, further comprising: aerosolizing the therapeutic agent from a non-aerosoled form into an aerosoled form prior to or during the initial first inhalation. 6. The method of claim 5, further comprising controlling the aerosolizing of the therapeutic agent for the initial first inhalation based on the inhalation velocity profile. 7. The method of claim 6, wherein controlling the aerosolizing of the therapeutic agent includes modulating a frequency of a vibrating member that aerosolizes the therapeutic agent using the inhalation velocity profile. 8. The method of claim 1, wherein dispensing the aerosoled form of the therapeutic agent includes generating a driving pressure for assisting in a delivery of the therapeutic agent into the user's lung during the initial first inhalation. 9. The method of claim 8, further comprising: modulating the driving pressure based on the derived inhalation velocity profile and responsive to an inhalation velocity of the initial first inhalation. 10. The method of claim 9, wherein modulating the driving pressure includes maintaining a substantially uniform delivery of therapeutic agent over a period of in which the therapeutic agent is dispensed. 11. The method of claim 1, wherein the therapeutic agent comprises insulin, mammalian insulin, human insulin or synthetically derived insulin. 12. The method of claim 1, wherein the therapeutic agent comprises a therapeutic agent for treatment of asthma. 13. The method of claim 1, wherein the therapeutic agent comprises an amino-sulfonyl-benzoate compound, furosemide, bumetanide, torsemide or ethacrynic acid. 14. The method of claim 1, wherein the desired amount is based on the derived inhalation velocity profile and one or more characteristics of the therapeutic agent wherein, the one or more characteristics includes at least one of a particle size, particle weight and absorptiveness of the therapeutic agent. 15. The method of claim 1, wherein signaling the user when the desired amount of the therapeutic agent has been dispensed includes causing the inhaler to generate an audible beep. 16. The method of claim 1, wherein signaling the user when the desired amount of the therapeutic agent has been dispensed includes causing the inhaler to cease generating an audible beep.

Details for Patent 10,307,551

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	October 28, 1982	10,307,551	2036-09-13
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	December 29, 2015	10,307,551	2036-09-13
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	August 06, 1998	10,307,551	2036-09-13